A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Bemnifosbuvir in Healthy Adult Japanese Subjects
Latest Information Update: 22 Jun 2023
At a glance
- Drugs Bemnifosbuvir (Primary)
- Indications COVID 2019 infections; Hepatitis C
- Focus Pharmacokinetics
- Sponsors Atea Pharmaceuticals
Most Recent Events
- 22 Jun 2023 New trial record